GARRE1

Across TCGA pan-cancer cohorts, GARRE1 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated GARRE1 data layer compared with 32 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher GARRE1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GARRE1 expression acts as an unfavorable survival marker.

KIRP, LIHC, and OV are the cancer types where GARRE1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.132	0.904	<.001	36	view →
LIHC	OS	Median	All	0.136	0.710	<.001	18	view →
OV	OS	Median	IV	0.022	0.760	<.001	12	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
LGG	OS	Median	All	0.214	0.889	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
SKCM	DFS	Median	All	0.546	0.734	.016	1	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

GARRE1–KIRP (OS)

Open the KIRP breakdown →